Silence Therapeutics plc Announces Completion Of Merger With Intradigm Corporation And Issue Of New Shares
Published: Jan 06, 2010
London, UK 5 January 2010 Silence Therapeutics plc ("the Company") (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference). The enlarged company, named Silence Therapeutics, possesses multiple RNAi discovery, development and delivery technologies, an advancing internal and partnered product pipeline and a broad portfolio of intellectual property. The merged company believes that its expanded business will facilitate more deals of greater value with the pharmaceutical industry by offering potential partners a choice of technologies to deliver RNAi molecules to diseased tissue. Additionally, Silence Therapeutics will actively develop and advance its own RNAi therapeutic candidates.